FDA Expedites Review of Telix Scan for Prostate Cancer Detection
The FDA has granted Fast Track designation to Telix Pharmaceuticals' BiPASS program, an investigational gallium-based PET scan for prostate cancer. This designation aims to accelerate the development and review process for the scan, which could potentially help men avoid unnecessary biopsies.
Want more?
Open NewsSnap.ai for the full app experience, including audio, personalization, and more news tools.